Systemic sclerosis & Raynaud's
Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease
Primary result · Rate of decline in FVC (ml/year)Result — go to the resultDifference 25.3 ml/year 95% CI −28.9 to 79.6Authors' conclusion
Patients with lcSSc may develop progressive fibrosing ILD. By targeting pulmonary fibrosis, nintedanib slows decline in lung function in patients with lcSSc and ILD.
Study context
- Population
- Patients with limited cutaneous systemic sclerosis (lcSSc) and interstitial lung disease (ILD) treated in the SENSCIS trial
- Participants
- 277 patients
- Comparison
- Nintedanib vs placebo in patients with lcSSc and ILD
- Primary endpoint
- Rate of decline in FVC (ml/year)
- Follow-up
- 52 weeks
Methodological detailsplacebo-controlled
- Placebo-controlled
Primary result
As reported in the abstract
Difference
25.3 ml/year
95% CI −28.9 to 79.6
By group
Placebo
−74.5
SE 19.2 · ml/year
Nintedanib
−49.1
SE 19.8 · ml/year
Nintedanibvs Placebo
difference 25.3 ml/year (95% CI −28.9 to 79.6)
Further findings
Mean, ml
| Outcome | Nintedanib | Placebo |
|---|---|---|
| Mean change in FVC (249 patients with data) · week 52 | −39.1 (SE 22.2) | −86.4 (SE 21.1) |
- Mean change in forced vital capacity (FVC) from baseline in SENSCIS-ON (183 patients with data): Placebo, then nintedanib in SENSCIS-ON mean −41.5 (SE 24.0) ml
- Mean change in FVC from baseline in SENSCIS-ON (183 patients with data): Nintedanib continued in SENSCIS-ON mean −45.1 (SE 19.1) ml
Original publication
Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease. Rheumatology (Oxford). Published 9 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →